Glucagon-like peptide-1 (GLP-1) displays concentration-dependent effects on metabolism, appetite and angiogenesis; therefore, accurate determination of circulating GLP-1 concentrations is important. In this study, we compared GLP-1 concentrations in venous versus arterialized blood in both fasted and fed conditions. Venous and arterialized blood samples were obtained simultaneously from 10 young, healthy men before and 30, 60 and 120 min after ingestion of 75 g glucose. Plasma GLP-1 concentrations increased in response to glucose ingestion (time effect, P < 0.01) and to a lesser extent in venous versus arterialized plasma (time × arterialization interaction, P < 0.01). Accordingly, the plasma incremental area under the curve was lower in 
INTRODUCTION
Postprandial glucagon-like peptide-1 (GLP-1) concentrations appear to mediate many of the beneficial changes in metabolism and feeding behaviour after bariatric surgery (Drucker, 2018) . Consequently, GLP-1 is a major target in diabetes research (Drucker, 2018) , and various nutritional, pharmacological and surgical methods are being explored with the intention of elevating the circulating GLP-1 availability and/or action (Edwards et al., 2001; Gonzalez, Veasey, Rumbold, & Stevenson, 2013; Jirapinyo, Jin, Qazi, Mishra, & Thompson, 2018; Nauck, Meier, Cavender, Abd El Aziz, & Drucker, 2017) . Much of the evidence supporting mechanistic roles of GLP-1 involves exogenous agonists or c 2018 The Authors. Experimental Physiology c 2018 The Physiological Society dipeptidyl peptidase IV (DPPIV) inhibitors, but there is also evidence that endogenous GLP-1 regulates insulin secretion and appetite from studies using GLP-1 receptor antagonists or physiological infusions (Aulinger et al., 2014; Tan et al., 2017) . Given that the effects of GLP-1 are concentration dependent (Aronis, Chamberland, & Mantzoros, 2013; Gonzalez et al., 2015; Nauck et al., 1993; Verdich et al., 2001) , accurate determination of peripheral exposure to GLP-1 is especially important.
In the fasted state, arteriovenous differences in GLP-1 concentrations across the leg have been reported during GLP-1 I.V. infusion (Asmar et al., 2017) . Venous sampling, therefore, might not determine tissue exposure to GLP-1 accurately. As GLP-1 is the major
New Findings

• What is the central question of this study?
Glucagon-like peptide-1 (GLP-1) is an important obesity/diabetes target, with effects dependent on circulating GLP-1 concentrations. Peripheral tissues extract GLP-1; therefore, sampling venous versus arterialized blood might provide different GLP-1 concentrations. This study examined whether arterialization alters GLP-1 concentrations during fasting and feeding.
• What is the main finding and its importance?
This study demonstrates that venous blood provides lower postprandial but not fasting GLP-1 concentrations versus arterialized blood. Therefore, when accurate assessment of postprandial peripheral availability of GLP-1 is required, blood sampling methods should be considered carefully, reported clearly, and arterialization is recommended.
incretin hormone (Drucker, 2018; Holst, 2007) , these arteriovenous differences could alter inferences regarding the relationship between postprandial GLP-1 and insulinaemia. Moreover, if differences between venous and arterialized blood are not consistent, then comparisons between studies using different blood sampling methods would be problematic. Indeed, blood sampling methods for GLP-1 measurement commonly vary between studies, with samples from capillary, arterial, arterialized or venous blood (Asmar et al., 2017; Gonzalez et al., 2015; Green, Gonzalez, Thomas, Stevenson, & Rumbold, 2014) , albeit arterial blood is much less frequently sampled owing to the greater technical challenge.
However, to date, no study has ever examined whether postprandial GLP-1 concentrations differ in venous compared with arterialized blood, and thus whether the method of blood sampling has implications for determining the relationship between GLP-1 and insulinemia (i.e. the incretin effect).
The primary aim of the present study was to assess whether venous blood exhibits concentrations of GLP-1 that are representative of arterialized blood, with a secondary aim to consider whether any apparent discrepancy affects the expected relationship between postprandial GLP-1 and insulinaemia. We hypothesized that postprandial GLP-1 concentrations would be lower in venous compared with arterialized blood and that this would alter the relationship between GLP-1 and insulinaemia.
METHODS
Ethical approval
The data presented in this study include plasma samples collected as part of a wider study (registered on clinicaltrials.gov as NCT02852044), but all data reported here are new and have not been published previously, apart from the participant characteristics and mean insulin concentrations (Edinburgh et al., 2017 
Participants and study design
Ten young, healthy men (mean ± SD; age, 23 ± 3 years; body mass index, 23.3 ± 1.8 kg m 2 ) undertook a 75-g oral glucose tolerance test (OGTT) after an hour of rest, with blood sampled from each arm, comprising one arterialized and one non-arterialized vein, simultaneously (Edinburgh et al., 2017) . Inclusion criteria included age 18-49 years, healthy males. Exclusion criteria included diagnosis of any bleeding disorder or taking medication that impacts blood coagulation, diagnosis of metabolic disease, or any other contraindications to the procedures in the present study.
Oral glucose tolerance test, blood sampling and analysis
After a 10-h overnight fast and 24 h of dietary and physical activity control, participants arrived in the laboratory at 08.00 ± 01.00 h. UK and Mercodia AB, Uppsala, Sweden, respectively; intra-assay coefficients of variation both <7%). The antibodies used in the GLP-1 assay are specific to both GLP-1 7-36 and GLP-1 9-36 and thus this assay captures total GLP-1 concentrations. Furthermore, the recovery is 90-110% and there is no significant cross-reactivity with GLP-2, glucose-dependent insulinotropic polypeptide, glucagon or oxyntomodulin (Bak et al., 2014) . The intra-and interassay coefficients of variation are <5 and <12%, respectively.
Statistical analysis
Statistical analyses were performed in GraphPad Prism (version 7; GraphPad Software, San Diego, CA, USA) and SPSS (version 24; IBM SPSS Statistics, Armonk, NY, USA). Data are presented as means ± SD in the text, whereas error bars in figures are 95% confidence intervals (CIs) normalized to remove between-subject variance for within-subject designs (Loftus & Masson, 1994) . The area under the curve (AUC) and incremental area under the curve (iAUC) were calculated using the trapezoidal rule. The Matsuda insulin sensitivity index (ISI Matsuda ) was calculated as previously described (Edinburgh et al., 2017; Matsuda & DeFronzo, 1999) . Before statistical analyses, residuals of comparisons were checked for normality using the 
RESULTS
Venous-arterialized differences in GLP-1 concentrations
After glucose ingestion, plasma GLP-1 concentrations increased (time effect, P < 0.01) and to a lesser extent in venous versus arterialized plasma (time × arterialization interaction, P < 0.01; Figure 1a 
Relationships between variables
Peak arterialized GLP-1 concentrations demonstrated a strong negative correlation with the venous-arterialized difference in peak GLP-1 concentrations (r 2 = 0.85; P < 0.001; Figure 2a ). However, the relationship between ISI Matsuda and the venous-arterialized difference in GLP-1 AUC was weak (r 2 = 0.03; P = 0.62).
Postprandial peak GLP-1 concentrations determined in arterialized plasma displayed a strong relationship with postprandial peak arterialized insulin concentrations ( Figure 2b ; r 2 = 0.64, P < 0.01).
Likewise, postprandial peak GLP-1 concentrations determined in venous plasma also displayed a strong relationship with postprandial peak arterialized insulin concentrations ( Figure 2b ; r 2 = 0.62, P < 0.01). 
DISCUSSION
The present study provides the first evidence that venous plasma provides lower postprandial but not fasting GLP-1 concentrations compared with arterialized plasma, with the absolute magnitude of these differences being amplified at higher GLP-1 concentrations.
Therefore, future studies should carefully consider the sample method for determination of GLP-1 availability. The difference in GLP-1 concentrations between arterialized and non-arterialized blood samples does not, however, appear to have implications for determining the relationship between GLP-1 availability and postprandial insulinaemia.
Determination of the circulating concentrations of GLP-1 is essential for appropriate inferences regarding peripheral actions of GLP-1. GLP-1 displays concentration-dependent effects on satiety (Verdich et al., 2001) , glucose-induced insulin secretion (Nauck et al., 1993) and angiogenesis (Aronis et al., 2013) . The difference in measured GLP-1 concentrations between venous and arterialized plasma in the present data ranged from −20 to 7 pmol l −1 . These differences are biologically meaningful, as they are greater than the Thompson, D., Gonzalez, J.T., unpublished observations), and equate to >10 units on a typical visual analog scale for hunger, satiety or appetite (Verdich et al., 2001) . Therefore, interpretations drawn from studies reporting effects on GLP-1 availability should be made with careful consideration of the blood sampling method in mind.
Glucagon-like peptide-1 exists in at least two forms in humans, with GLP-1 7-36 known to be the primary activator of the classical GLP-1 receptor. We chose to assess total GLP-1 rather than GLP-1 concentrations for two reasons: first, total GLP-1 concentrations are the best indication of GLP-1 secretion in humans in vivo (Holst, 2007) ; second, we wanted to rule out changes in GLP-1 concentrations attributable to activity of DPPIV across tissue beds.
In humans, GLP-1 is almost entirely secreted as GLP-1 7-36 by the enteroendocrine cells of the intestine (Holst, 2007; Orskov, Rabenhoj, Wettergren, Kofod, & Holst, 1994) . GLP-1 7-36 is subsequently cleaved by DPPIV, which acts on GLP-1 7-36 in the endothelium, liver and circulating plasma (Holst, 2007) . Furthermore, DPPIV is secreted by adipose tissue (Lamers et al., 2011; Sell et al., 2013 One of the primary actions of GLP-1 is to potentiate glucoseinduced insulin secretion (Drucker, 2018; Holst, 2007) , i.e. the incretin effect. In order to assess whether arterialization of the veins has implications for inferences of the incretin effect, we assessed the relationship between peak arterialized insulin concentrations and GLP-1 concentrations determined in arterialized or venous plasma.
Both arterialized and venous peak GLP-1 concentrations were strongly and positively correlated with peak arterialized insulin concentrations (both displaying an r 2 > 0.6). This suggests that both GLP-1 and insulin are removed from arterial blood at a similar rate, and thus, arterialization does not appear to influence the interpretation of the incretin effect. Whether this relationship holds for different populations remains to be seen.
The present study was limited by the small sample size (which can overestimate effect sizes) and the relatively homogeneous cohort of males. Therefore, further work in larger cohorts, with females and individuals differing in weight status, will be useful to make these data more generalizable. There is little physiological rationale to expect that other human cohorts would differ in the direction of venous-arterialized difference observed in the present study, but the magnitude of this venous-arterialized difference could be altered in other cohorts. 
